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ABSTRACT 
Acute massive pulmonary embolism is characterized by obstruction of the pulmonary arterial 
tree that exceeds 50% of the cross-sectional area causing acute and severe cardiopulmonary 
failure from right ventricular overload. Systemic thrombolytic therapy is recommended as 
standard, first-line treatment in patients with massive pulmonary embolism unless 
contraindicated and catheter directed therapies, including low dose thrombolytic administration 
directly into thrombus and mechanical thrombectomy can be adjunctive or used as an alternative 
to systemic treatments. This literature review researched articles looking both systemic 
thrombolysis and endovascular techniques for the treatment of acute massive pulmonary 
embolism with an emphasis on long term clinical outcomes. Study results demonstrated the 
efficacy and safety of systemic thrombolysis and catheter directed therapies as well as adverse 
effects; however, further randomized trials are needed, as acknowledged by many of the authors 
included in this paper, comparing both treatment options for hemodynamically unstable patients 
with emphasis on long term sequalae.  
 
Keywords:  anticoagulation, prognosis, pulmonary embolism, thrombectomy, and thrombolytics. 
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Introduction 
 
Systemic thrombolysis is standard, first-line treatment for a patient presenting with 
hemodynamically unstable pulmonary embolism, but data from randomized trials using catheter 
directed techniques is gaining attention as a viable option for patients who have contraindications 
to high-dose systemic thrombolysis. A meta-analysis of 594 patients from six prospective and 29 
retrospective studies demonstrated a significant reduction in complication rates with catheter 
directed therapies and a clinical success rate of 86.5% compared to 77% following systemic 
thrombolysis (Kuo, et al., 2009). This study supported both safety and efficacy in treating 
massive pulmonary embolism with catheter directed thrombectomy and intraclot thrombolysis.  
Long term outcomes following massive pulmonary embolism treatment provide 
beneficial statistical data for clinicians treating these patients. The use of quality of life surveys, 
dyspnea-questionnaires and a 6 minute walk test are tools that help measure outcomes and are 
valuable clinical and physiological predictors of long term prognosis (Kahn, et al., 2017). Data 
acquisition following pulmonary embolism could prove beneficial in determining appropriate 
treatment by looking at the long-term sequela of post massive pulmonary thrombus, especially 
those receiving systemic thrombolytics or endovascular therapies.  
Statement of the Problem: 
Deciding on a treatment plan for a patient presenting with an acute massive pulmonary 
embolism can be challenging for some clinicians. Systemic thrombolytic therapy continues to be 
standard, first-line therapy, but new technologies using catheter directed techniques with a 
combination of thrombectomy and intraclot thrombolysis are demonstrating safety and efficacy 
and are gaining support in the medical community. There is limited long term data regarding 
morbidity and mortality of patients treated for massive pulmonary embolism. This information 
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could help guide clinicians in deciding on a treatment option that could provide immediate 
therapy to hemodynamically unstable patients while at the same time providing improvement in 
quality of life long term. 
Research Questions: 
In patients presenting with acute massive pulmonary embolism, how does the use of 
systemic thrombolytics compare in efficacy and safety over catheter directed therapies? Is there 
improvement in quality of life, dyspnea, and functional capacity with catheter directed 
thrombolysis and thrombectomy compared to systemic thrombolysis? 
This scholarly project looked at the efficacy and safety of both therapies for massive 
pulmonary embolism to determine the best option for clinicians when deciding treatment for 
their patients by comparing statistical data of short-term efficacy as well as long-term sequela. 
Pathology of Pulmonary Embolism: 
Pulmonary embolism (PE) is defined as obstruction of the pulmonary vasculature and 
risk factors that are acquired and inherited may contribute to someone developing this disease. 
Genetic risk factors typically involve disorders of clotting factors and include protein C 
deficiency, protein S deficiency, factor V Leiden, antithrombin deficiency, and 
hyperhomocysteinemia. Acquired risks include, but are not limited to obesity: age, estrogen 
therapy, pregnancy, prolonged immobility, cancer, trauma, and post-surgery (Giordano, Jansson, 
Young, Hogan, & Kabrhel, 2017).  
Thrombus occurs when there is a disruption in the mechanisms between blood 
coagulation and anticoagulation, and PE can follow when thrombus from a deep vein thrombosis 
(DVT) breaks off and travels to the pulmonary circulation, although non-thrombotic material like 
fat, tumor or air can also be the source (Giordano, Jansson, Young, Hogan, & Kabrhel, 2017). 
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Therapy should be initiated promptly because of increased mortality and morbidity associated 
with PE and understanding the risks for venous thromboembolism (VTE) and how a patient may 
present can expedite diagnosis and subsequent treatment.   
Venous stasis, hypercoagulability and local trauma to vessel walls are events known as 
Virchow’s triad, and many patients with VTE are diagnosed with one of these during their 
history and physical examination.  When DVT develops, usually in the lower extremities, 
vascular congestion can cause swelling and pain proximal to the site of obstruction, although 
these symptoms can be subtle or nonexistent. If the DVT forms in a large vessel, it is more likely 
to dislodge and embolize the pulmonary artery occluding some degree of the vasculature. Small 
emboli may only obstruct subsegmental arteries and spontaneously lyse without clinical 
consequences. However, large thrombi can straddle the bifurcation or obstruct the entire 
pulmonary outflow tract, increasing the strain on the right heart and leading to severe 
hypotension and death (Giordano, Jansson, Young, Hogan, & Kabrhel, 2017).  
Diagnosis of Pulmonary Embolism 
 Turan et al. (2017), conducted a retrospective analysis of 196 patients suspected of 
having pulmonary embolism and a subsequent D-dimer and computed tomography angiography 
(CTA) was performed for diagnosis. This study used clinical scoring systems, comparing them to 
patients with and without pulmonary embolism to help guide clinicians in managing their 
patients and add to their ability to diagnose pulmonary embolism, especially practitioners in rural 
communities. It was noted by the authors that CTA is important in visualizing pulmonary 
embolism, but has a high radiation and contrast exposure.  
The study tested a hypothesis that clinical scoring and D-dimers can aide in guiding 
clinicians in managing their patients with suspected pulmonary embolism by comparing their 
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findings to diagnostic imaging. The analysis employed an empirical scoring system as well as 
Geneva, Wells, and Miniati scoring systems to help classify patients as having low, intermediate 
or high clinical probability of PE and then compared the results to CT angiography for 
correlation.  The study group included 107 males (54.6%) and 89 females (45.4%) suspected of 
PE; their mean age was 64.18 ± 17.44. There was no statistically significant relationship between 
the presence of PE and gender (p = 0.064). The sensitivity of the various scoring systems for PE 
was found as 94.9% for empirical scoring, 89.7% for the Wells criteria, 84.6% for Geneva 
scoring, and 92.3% for the Miniati system. There was no PE in any patient with a normal D-
dimer level and a low probability score in any scoring system. 
Treatment Options for Acute Massive Pulmonary Embolism 
Treatment options for pulmonary embolism depend on the hemodynamic stability of the 
patient and the clot burden. Therapy consists of anticoagulation, systemic thrombolytics and 
endovascular therapies including mechanical thrombectomy and intraclot thrombolysis. 
Rheolytic thrombectomy removes clots by injecting high pressure saline into the thrombus and 
breaking it into fragments. The clot is then suctioned out of the artery. A retrospective study of 51 
consecutive patients that presented with acute submassive or massive pulmonary embolism and 
were subsequently treated with AngioJet rheolytic therapy was conducted by Chechi et al. (2009) 
to appraise the impact of this therapy both clinically and angiographically. Figure 1 shows post-
procedural angiographic data.  
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Figure 1 
Improvement in obstruction, perfusion, Miller indexes, and systolic pulmonary artery 
pressure before and after rheolytic thrombectomy according to hemodynamic 
compromise (i.e., shock, red bars; hypotension, green bars; right ventricular dysfunction, 
blue bars) Chechi et al. (2009). 
 
The study hypothesized that there was a significant clinical benefit to mechanical 
removal of the thrombus as opposed to management with systemic therapy in patients with 
hemodynamically significant compromise. The data demonstrated safety and efficacy in treating 
hemodynamically unstable patients with massive pulmonary embolism. Loco-regional 
fibrinolysis, as it has been carried out in historical trials, may carry a lower risk of bleeding, 
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because of the low dose of drug administration; however, due to its ease and availability, 
systemic route is currently recommended for thrombolysis in acute PE.  
 The use of systemic thrombolytics increases the risk of hemorrhage when compared to 
heparin alone or when thrombolysis was combined with placebo. A Cochran Review meta-
anaylsis combined data from 17 trials with 2167 participants and looked at outcomes of patients 
randomly assigned to thrombolytic agents followed by heparin versus other therapies. The study 
showed low quality evidence that thrombolytics reduce death following acute pulmonary 
embolism compared to systemic heparin; however, the studies demonstrated a reduction in 
recurrance rates and an increased risk of hemorrhage when using thrombolytic therapies (P = 
0.001) (Hao, Dong, Yue, & Liu, 2015). Major and minor bleeding remain a concern when using 
thrombolytics even though evidence suggest these agents dissolve clots more rapidly than 
heparin and reduce the death rate associated with PE.  
Systemic thrombolysis also demonstrates an increased risk of hemorrhage when 
compared to catheter directed intraclot lytics. A meta-analysis of 594 patients from six 
prospective studies and 29 retrospective studies that met the inclusion criteria were included in 
this systematic review evaluating the safety and efficacy of catheter directed therapy techniques 
for massive pulmonary embolism. The study demonstrated a significant reduction in 
complication rates with the use of catheter directed therapies and a clinical success rate of 86.5% 
compared to 77% following systemic thrombolysis (Kuo et al., 2009). The authors of this paper 
reported an estimated 20% risk of major hemorrhage with systemic thrombolysis; however, only 
minor and major procedural complications of 7.9% (95% CI 5.0 to 11.3) and 2.4% (95% CI 1.9 to 
4.3) respectively were given.      
Safety of Systemic and Endovascular Therapy 
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Deciding on a treatment plan for a patient presenting with an acute massive pulmonary 
embolism can be challenging for some clinicians. Systemic thrombolytic therapy continues to be 
standard, first-line therapy, but new technologies using catheter directed techniques with a 
combination of thrombectomy and intraclot thrombolysis are demonstrating safety and efficacy 
and are gaining support in the medical community. 
A meta-analysis of 594 patients from six prospective and 29 retrospective studies 
demonstrated a significant reduction in complication rates with catheter directed therapies and a 
clinical success rate of 86.5% (95% CI 82.2 to 90.2; 35 studies) compared to 77% following 
systemic thrombolysis (Kuo et al., 2009). The authors acknowledged treatment of massive 
pulmonary embolism with systemic thrombolysis is standard of care, but that contraindications 
and time constraints can increase the risks of adverse events associated with this therapy.   
 A retrospective, unblinded study was performed in Japan investigating the clinical 
outcomes of 221 patients diagnosed with acute pulmonary embolism and treated with systemic 
therapy. Anticoagulation therapy was performed in 100 patients and thrombotic therapy was 
performed in 121 patients. For patients with right heart strain, thrombolysis demonstrated a 
favorable outcome and no significant complications from hemorrhage when compared to 
anticoagulation alone (Nakamura et al., 2005). Figure 2 shows Clinical events during the hospital 
stay.   
  
                                            Anticoagulation alone          Thrombolysis               P          
With prolonged shock 1/4 (25%) 5/12 (42%) >0.99 
Hemodynamically stable 8/91 (9%) 10/100 (10%) 0.81 
With RV afterload stress 4/15 (27%) 5/42 (12%) 0.22 
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Without RV afterload stress 4/30 (13%) 5/32 (16%) >0.99 
               Major bleeding 6/100 (6%) 16/121 (13%) 0.11 
Values shown were (no. of death cases + no. of cases with recurrent APTE)/no. of total cases in 
each group. Only for major bleeding, values shown were no. of cases with major bleeding/no. of 
all study cases. RV=right ventricular, APTE=acute pulmonary thromboembolism (Nakamura, et 
al., 2005). 
 
The rate of death and recurrence of acute pulmonary thromboembolism in the 
anticoagulation group was similar to that in the thrombolytic group (9% versus 10%, 
respectively, P-0.81). It was noted that the dosage of thrombolysis is less in Japan than that used 
in the United States.  A potential source of bias was the non-randomized assignment of patients 
and the choice of treatment being at the discretion of the attending physicians. 
Treating elderly patients can be challenging due to comorbidities and the increased risks 
of hemorrhage. Ipek, et al., evaluated the effectiveness and safety of thrombolytic therapy in 
elderly patients with pulmonary embolism. This study added to existing knowledge concerning 
hemorrhagic complications associated with thrombolysis by including elderly patients who 
historically receive inadequate treatment. The data collected on 363 patients recruited for the 
study, including 205 subjects > 65 and 158 subjects < 65, demonstrated comparable hemorrhagic 
complications versus patients who received heparin therapy. Three of 51 (5.9%) elderly patients 
who were treated with thrombolytic therapy died at 30 days follow-up. One (1.9%) additional 
death was seen at 1-year follow-up in this group. In contrast, 11 (7.1%) patients died at 30 days 
and 20 (12.9%) patients died during the follow-up among elderly non-thrombotic group. These 
results show the effectiveness and safety of thrombolytic therapy in the elderly (Ipek et al., 
2015).  
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For those patients with relative contraindications to systemic high dose thrombolytic 
therapy, catheter directed procedures that employ mechanical thrombectomy as well as low dose 
intraclot thrombolysis have proven safety track records in both massive and submassive PE 
(figure 1). A multicenter registry and meta-analysis conducted by Bloomer et al. (2017), 
provided results in a paper investigating the safety of catheter-directed thrombolysis in the 
treatment of both acute massive and submassive pulmonary embolism. Comparison to systemic 
treatment was not conducted; however, the data demonstrated low bleeding complications with 
CDT. Of the 860 patients analyzed, 88% were considered submassive PE, potentially skewing 
the results of the safety data of massive PE treatment with CDT. The statistical analysis from the 
registry was combined with the pooled analysis from the 15 published studies and the data was 
justified in their conclusion.  
A 
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Figure 1. Thrombectomy procedure. a) Pulmonary arteriogram demonstrating thrombus within the 
pulmonary vasculature prior to thrombectomy using Penumbra’s Indigo System. b) Clot removed during 
thrombectomy. c) Post procedure pulmonary arteriogram demonstrating restoration of blood flow through 
pulmonary arteries. 
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Long Term Sequela   
 When treating hemodynamically unstable patients presenting with pulmonary embolism, 
it’s important to consider not only the immediate threat, but also long term sequela like quality of 
life. The ELOPE (Evaluation of Long-term Outcomes after PE) cohort study, through a 
comprehensive follow-up of patients diagnosed with pulmonary embolism, measured outcomes 
to include quality of life surveys, dyspnea-questionnaires and a six minute work walk distance up 
to 12 months post treatment. This relevant study looked at the outcomes of patients that were 
diagnosed with pulmonary embolism through a baseline computed tomography pulmonary 
angiogram and found specific clinical and physiological predictors of reduced improvement over 
time, providing new information on prognosis following pulmonary embolism ( Kahn et al., 
2017). Hemodynamically unstable patients may not do well once diagnosed and treated for 
massive pulmonary embolism (Kahn et al., 2014). This study demonstrated poor prognosis 
following PE but noted that the clinical significance of residual pulmonary vascular 
abnormalities in this outcome continues to be poorly understood. The data provided did show 
chronic thromboembolic pulmonary hypertension was found to range from 1 to 4% with a poor 
prognosis and a median survival of 12-24 months.  
 The paper published by Kahn et al. (2017), was reinforced by a meta-analysis looking at 
the long term effects of pulmonary embolism on right ventricular function, exercise tolerance 
and quality of life and assessed whether thrombolytic drugs affected these outcomes.    
Costs of Systemic Thombolytics versus Catheter Directed Treatment 
 Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and 
pulmonary embolism (PE), affects about 900,000 persons in the United States each year. 
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According to Dasta et al. (2015), patients admitted and receiving anticoagulation for PE had 
daily hospital costs of 2,981, 2,034 and 1,564 for their first three days of admission and the costs 
became stable following the third day. This was a retrospective claims analysis of 64,000 patients 
diagnosed with deep vein thrombosis or PE. The study also suggested that any change in the 
length of stay could significantly affect hospitalization costs. Another study by LaMori et al. 
(2015), examined the initial and subsequent length of stay in hospitals and associated charges in 
US hospitals in 2011and found that subsequent admissions were costlier than the initial 
admission. Many of the patients were also discharged to specialist nursing facilities incurring 
post-hospitalization charges. The median charge amounted to $37, 006 for the initial 
hospitalization with a mean hospital stay of 5.1 days. It was noted by the authors that appropriate 
anticoagulation and continuity of care may reduce incidence and frequency of hospital 
readmissions and thromboembolic morbidity and mortality.  
Discussion 
A review of the literature shows that systemic thrombolytics remains the gold standard 
for treatment of massive PE for patients without contraindications. The goal of any treatment is 
to decrease thrombus burden and return the patient to hemodynamic stability, while at the same 
time minimizing major bleeding risks and mortality. Catheter directed therapies allow for both 
low dose intraclot thrombolytics and mechanical thrombectomy and may prove beneficial for the 
long-term sequela related to massive pulmonary thrombus. Chronic thromboembolic pulmonary 
hypertension can be found in a small percentage of patients post pulmonary embolism which 
carries a poor prognosis, and although the clinical significance of residual pulmonary vascular 
abnormalities continues to be poorly understood, the literature review determined that patients 
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may not do well long term once diagnosed and treated with thrombolytics (Bloomer, et al., 
2017).  
The goal of any treatment for acute massive pulmonary embolism is to decrease 
thrombus burden and return the patient to hemodynamic stability, while at the same time 
minimizing major bleeding risks, mortality and long term sequela. A comprehensive literature 
review of previous research was conducted focusing on the risks and benefits of both systemic 
and endovascular therapies for massive pulmonary embolism by analyzing historical data 
through a search of PubMed, CINALHL and Cochran. Catheter directed therapies allow for both 
low dose intraclot thrombolytics and mechanical thrombectomy and may prove beneficial for the 
long-term sequela related to massive thrombus. However, systemic thrombolytics remains the 
gold standard for treatment of massive PE for patients without contraindications. Chronic 
thromboembolic pulmonary hypertension can be found in a small percentage of patients post 
pulmonary embolism which carries a poor prognosis and although the clinical significance of 
residual pulmonary vascular abnormalities continues to be poorly understood, the literature 
review determined that patients may not do well long term once diagnosed and treated with 
thrombolytics (Kahn et al., 2014).  
In Patients Presenting With Acute Massive Pulmonary Embolism, How Does the Use of 
Systemic Thrombolytics Compare in Efficacy and Safety over Catheter Directed 
Therapies?  
As the first line treatment for hemodynamically unstable patients presenting with 
pulmonary embolism, systemic thrombolysis is well tolerated and efficacious; however, it may 
be contraindicated in patients with prior intracranial hemorrhage, cerebral vascular lesions, 
malignancy, active bleeding, bleeding diathesis or in patients older than 65.  
TREATMENT OF ACUTE MASSIVE PULMONARY EMBOLISM 18 
Historically, elderly patients receive inadequate treatment with thrombolysis due to 
concerns of hemorrhagic complications associated with the above conditions. Ipek et al. (2015) 
found comparable hemorrhage rates between patients >65 that didn’t receive thrombolysis to 205 
subjects >65 and 158 subjects <65 that were treated with systemic thrombolysis. Regarding long 
term follow-up, three of 51 (5.9%) elderly patients who were treated with thrombolytic therapy 
died at 30 days follow-up. One (1.9%) additional death was seen at 1-year follow-up in this 
group. In contrast, 11 (7.1%) patients died at 30 days and 20 (12.9%) patients died during 
follow-up among elderly non-thrombolytic group. These results show the effectiveness of 
thrombolytic therapy, particularly in patients >65. The effects of comorbid conditions on patient 
outcomes may be a source of potential bias.  
 In a retrospective, unblinded study investigating clinical outcomes of 221 patients 
diagnosed with acute pulmonary embolism and treated with thrombolytic therapy, researches 
from Japan demonstrated favorable outcomes and no significant complications from hemorrhage 
when compared to anticoagulation alone. Although the differences in death and recurrence of 
acute pulmonary thromboembolism between thrombolytic and anticoagulation groups didn’t 
show statistical significance, the thrombolytic group tended to demonstrate better outcomes. 
Furthermore, there was no significant difference in the rate of major bleeding between 
thrombolytic and anticoagulation groups (Nakamura et al., 2005).   
 Throughout this research, systemic thrombolytic therapy has continued as first line 
treatment for PE even though some studies have shown higher bleeding complications as well as 
multiple contraindications when compared to anticoagulation alone.  Alternative treatments with 
endovascular therapy using catheter directed techniques to mechanically macerate and remove 
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clots and/or deliver intraclot thrombolytics continues to show promising results and low 
complication rates.  
A meta-analysis of 594 patients from six prospective and 29 retrospective studies was 
included in a systematic review evaluating the safety and efficacy of catheter directed therapy 
techniques for massive pulmonary embolism. The study demonstrated a significant reduction in 
complication rates with the use of catheter directed therapies and a clinical success rate of 86.5% 
compared to 77% following systemic thrombolysis. The clinical success of this study was 
defined as stabilization of hemodynamics, resolution of hypoxia and survival at discharge. 
Treatment included mechanical fragmentation and/or aspiration of clot as well as intraclot 
thrombolytics. A source of potential bias was found in the fact that only 60% of patients received 
intraclot lytics during catheter directed thrombectomy and the study didn’t compare systemic 
thrombolytics to one specific catheter directed therapy. This meta-analysis evaluated short-term 
clinical success, but as with most studies reviewed, long term data looking at patient’s quality of 
life post massive pulmonary embolism was not included.  
Is There Improvement in Quality of Life, Dyspnea, and Functional Capacity with use of 
Catheter Directed Thrombolysis and Thrombectomy Compared to Systemic Thrombolysis?   
Kahn et al. (2014) conducted a one year comprehensive follow-up of patients diagnosed 
with acute pulmonary embolism using measured outcomes to include quality of life surveys, a 
dyspnea questionnaire and a 6-minute walk distance at baseline and at 1,3,6, and 12 months. This 
relevant study looked at the outcomes of patients that were diagnosed with pulmonary embolism 
through a baseline computed tomography pulmonary angiogram. The study found specific 
clinical and physiological predictors of reduced improvement over time, providing new 
information on prognosis following pulmonary embolism. Although these patients were treated 
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with anticoagulants and not with systemic thrombolysis or catheter directed therapy, it did 
highlight the need to include measurement of one or more functional outcomes in studies of 
interventions to treat pulmonary embolism (Kahn et al., 2017). The study design was not 
appropriate to my research question but it did show alternative treatment outcomes and 
techniques of data acquisition.  
Sista et al. (2017) looked at persistent right ventricular dysfunction, functional capacity 
limitation, exercise intolerance, and quality of life (QoL) impairment following pulmonary 
embolism and found 4% of survivors develop chronic thromboembolic pulmonary hypertension 
stemming from residual pulmonary artery obstruction and a mean pulmonary artery pressure 
greater then 25 mmHg. The study found evidence that many more have poor QoL and exercise 
intolerance following PE, termed post-PE syndrome. This syndrome may be the result of 
unresolved thrombus causing increased right heart pressure in the months and years following 
PE. The data justified the conclusions demonstrating a substantial reduction in quality of life and 
shorter walking distances of patients post pulmonary embolization compared to population 
norms. The study excluded patients that were treated exclusively with embolectomy and was 
unclear regarding thrombolytics and patient outcomes. 
The ELOPE (Evaluation of Long-term Outcomes after Pulmonary Embolism) Study is a 
prospective, observational, multicenter cohort study of patients with a newly diagnosed, first 
episode pulmonary embolism with specific determinants of poor outcomes. This relevant study, 
determined that patients may not do well once diagnosed and treated with thrombolytic 
therapies; however, the clinical significance of residual pulmonary vascular abnormalities in this 
outcome continues to be poorly understood. Chronic thromboembolic pulmonary hypertension 
was found to range from 1 to 4% with a poor prognosis and a median survival of 12-24 months. 
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The data provided in the article justified the conclusion of poor long-term prognosis following 
pulmonary embolism by researching several prospective and retrospective studies. The authors 
of this article are attempting to rationalize the need for a prospective, observational, multicenter 
cohort study of patients with newly diagnosed pulmonary embolism in order to determine 
potential poor outcomes by identify clinical, anatomic and physiological determinants. The 
question of what is the best treatment option for patients presenting with hemodynamically 
unstable massive pulmonary embolism was not definitively answered in my review of the 
literature and shows that further research, comparing systemic thrombolytic therapy to catheter 
directed treatments, is indicated.    
  
Applicability to Medical Practice 
Diagnosis of PE uses a combination of techniques including a D-dimer, CTA and scoring 
systems like Geneva, Wells, and Miniati and studies have demonstrated a low probability of 
pulmonary embolism if the D-dimer is normal and the scoring system used shows a low 
probability. This is important data for clinicians working in rural areas where access to CTA 
might not be available. Whether using advanced technologies or clinical judgement and PE 
scoring systems combined with laboratory values, the question facing clinicians is how to treat. 
This is often based on how hemodynamically stable the patient is and the contraindications to 
various treatment options. As the research in the literature demonstrates, there are pros and cons 
to all therapies and patient selection is critical. Thrombolysis remains the gold standard of 
treatment for patients presenting with hemodynamically unstable pulmonary embolism but the 
data demonstrates similar short-term outcomes in most studies when compared to CDT.  The use 
of systemic thrombolytics increases the risk of hemorrhage when compared to heparin alone or 
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when combined with placebo but no consensus was found for increased hemorrhage when 
compared to catheter directed therapies. A Cochran review meta-analysis did find reduction in 
recurrence rates with systemic thrombolysis but also found an increase risk in hemorrhage when 
compared to anticoagulation (Hao, Dong, Yue, & Liu, 2015). As with most trials the authors 
agreed that more randomized studies are needed to assess safety and efficacy of thrombolytics.  
Catheter directed therapy affords the opportunity to mechanically remove thrombus and 
at the same time infuse or bolus low dose thrombolytics directly into clot. This has the potential 
to reduce the hemorrhage seen with high dose thrombolytics. Several new technologies are being 
used today showing great efficacy and low complication rates. The Indigo Mechanical 
Thrombectomy Catheter uses continuous aspiration mechanical thrombectomy with high level 
suction to remove clots and can be used as a first line therapy. This is just one device of many 
showing promising results. Chechi et al. (2009) conducted a retrospective study of 51 
consecutive patients that presented with acute submassive or massive pulmonary embolism over 
a seven year period, that were subsequently treated with AngioJet rheolytic therapy, to appraise 
the impact of this therapy both clinically and angiographically. The data demonstrated safety and 
efficacy in treating patients with massive pulmonary embolism and concluded that large-scale 
randomized clinical trials comparing systemic thrombolytic to rheolytic thrombectomy are 
warranted.  This study highlights again the need for further trials comparing systemic therapy to 
endovascular intraclot thrombolysis and thrombectomy.  
The efficacy and safety of both systemic and catheter directed therapies appears 
comparable depending on which study you read, especially looking at short term outcomes. 
Several studies have looked at long-term sequela post pulmonary embolism and the role residual 
thrombus plays in quality of life measures. The clinical significance of residual pulmonary 
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vascular abnormalities continues to be poorly understood but there is agreement that these 
patients may not do well long-term due to chronic thromboembolic pulmonary hypertension.  
In conclusion, there is a need for prospective, observational, multicenter cohort studies 
comparing patients treated with systemic thrombolytics to catheter directed therapies in order to 
determine potential poor outcomes by identifying clinical, anatomic and physiological 
determinants. In addition, further research is needed in functional capacity limitation, exercise 
intolerance and quality of life impairment post hemodynamically unstable patients treated with 
both systemic thrombolysis and catheter directed therapy for a head to head comparison.  
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